TITLE

Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial

AUTHOR(S)
Giffins, Nicola S.; Hunter-Blair, Yan L.; Matthews, John N. S.; Coulthard, Malcolm G.
PUB. DATE
June 2007
SOURCE
Archives of Disease in Childhood;Jun2007, Vol. 92 Issue 6, p499
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: To determine whether the tissue plasminogen activator, alteplase, is more effective than heparin in preventing blood clots developing in children's haemodialysis central lines between dialysis sessions. Design: A prospective double-blind, within-patient multiperiod cross-over controlled trial of instilling a "lock" of either heparin 5000 U/mI or alteplase 1 mg/mI into the central lines of two children haemodialysed twice weekly, and seven dialysed thrice weekly, over 10 weeks. Setting: A UK paediatric nephrology unit. Main outcome measures: Weight of blood clot aspirated from the line at the start of the next dialysis session. Results: The odds of a clot forming was 2.4 times greater with heparin than alteplase (95% CI 1.4 to 4.0; p = 0.001), and when present they were 1.9 times heavier (31 vs 15 mg; 95% Cl 1.5 to 2.4; p<0.0005). There was no effect of inter-dialytic interval. One child required an alteplase infusion to clear a blocked line following a heparin lock. We subsequently changed our routine locks from heparin to alteplase. Comparing the year before and after that change, the incidence of blocked lines requiring an alteplase or urokinase infusion fell from 2.7 to 1.2 per child (p<0.03), and the need for surgical replacements from 0.7 to nil (p<0.02). Conclusion: Alteplase is significantly more effective than heparin in preventing clot formation in central haemodialysis lines. This reduces morbidity and improves preservation of central venous access. It is more expensive, though relatively economic if packaged into syringes and stored frozen until needed, but reduces the costs of unblocking or replacing clotted lines.
ACCESSION #
25471892

 

Related Articles

  • Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review. Firwana, Belal M.; Hasan, Rim; Ferwana, Mazen; Varon, Joseph; Stern, Aaron; Gidwani, Umesh // Avicenna Journal of Medicine;2011, Vol. 1 Issue 2, p29 

    Background and Objectives: Hemodialysis catheters are commonly used when renal replacement therapy is initiated. These catheters have significant complications. Among "locking" solutions used in an attempt to decrease these complications is recombinant tissue plasminogen activator (rt-PA). This...

  • Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient. Igaki, Naoya; Matsuda, Tomokazu; Yatani, Hirofumi; Kawaguchi, Takayuki; Kida, Aritoshi; Yanase, Kimihiko; Moriguchi, Rintarou; Sakai, Makoto; Tamada, Fumihiko; Goto, Takeo // Clinical & Experimental Nephrology;Dec2003, Vol. 7 Issue 4, p306 

    We report a patient with diabetic endstage renal disease with an initial platelet count of 17.6 × 104/mm3 who developed type-II heparin-induced thrombocytopenia (HIT) during the induction period of hemodialysis (HD) when unfractionated heparin was used. Because the recognition of the...

  • Do PPIs interact with aspirin? Garrett, Anna D. // Drug Topics;Aug2011, Vol. 155 Issue 8, p41 

    The article presents the summaries of studies about anticoagulation therapies. It highlights a study which explores the drug interaction between proton pump inhibitors (PPIs) and clopidogrel. It outlines another study which examines the benefits of using recombinant tissue-type plasminogen...

  • The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: influence on clotting of the extracorporeal system and hemostatic parameters. Ulbricht, K.; Bucha, E.; Pöschel, K. A.; Stein, G.; Wolf, G.; Nowak, G. // Clinical Nephrology;2006, Vol. 65 Issue 3, p180 

    Aim: The aim of our study was to investigate the use of polyethylene glycol (PEG)-Hirudin (PEG-H) as an anticoagulant in hemodialysis including drug monitoring with the Ecarin Clotting Time (ECT) in whole blood and to compare this regimen with standard anticoagulant unfractionated heparin (UFH)...

  • IN VITRO EFFECTS OF LOW MOLECULAR WEIGHT HEPARIN ON CLOT RATE.  // Heart;Oct2010 Supplement, pA54 

    An abstract of the article "In Vitro Effects of Low Molecular Weight Heparin on Clot Rate" by Shi Xu-bo and colleagues is presented.

  • tissue plasminogen activator.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2328 

    An encyclopedia entry for "tissue plasminogen activator," which refers to a natural enzyme that aids degrade blood clots by freeing plasmin from plasminogen, or it could also refer to a recombinant enzyme, produced by Escherichia coli in the laboratory, for use in the treatment of thrombosis.

  • `Clotbuster' saves women from heart attacks.  // New Scientist;2/19/94, Vol. 141 Issue 1913, p15 

    Reports on a study of the components of the blood's clotting system in women. `Clot buster' in premenopausal women; Level of inhibitor of tissue plasminogen activator (TPA); Link to resistance to cardiovascular disease.

  • Does adding vitamin K to warlarin improve anticoagulation control?  // Journal of Family Practice;Apr2008, Vol. 57 Issue 4, p221 

    The article discusses the implication of adding Vitamin K to warfarin in improving the occurrence of anticoagulation in adults in the U.S. Research shows that supplementation of Vitamin K help control anticoagulation in warfarin-treated patients with unexplained unstable anticoagulation. The...

  • Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. Speiser, Wolfgang; Wojta, Johann; Korninger, Christian; Kirchheimer, Johannes C.; Zazgornik, Jan; Binder, Bernd R. // Kidney International;Aug1987, Vol. 32 Issue 2, p280 

    The effect of hemodialysis on components of the fibrinolytic system was measured in 22 patients. Plasma levels of t-PA antigen, t-PA activity, u-PA antigen and plasminogen activator inhibitor were determined by means of immunological and functional assays. During hemodialysis, 11 patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics